01—Abstract
Summary
Summary of the 8-K filed July 3, 2025. Cited figures are marked; the original filing is the authoritative source.
AbbVie Inc. (ABBV) has filed a Current Report on Form 8-K on July 3, 2025, to provide an update on its financial outlook for the second quarter and full year of 2025.
The report highlights a significant pre-tax expense of $823 milliona related to acquired in-process research and development (IPR&D) and milestones in the second quarter. This expense is expected to have an unfavorable impact of $0.42 per share on both GAAP and adjusted non-GAAP diluted earnings per share for the quarter. While the company's full-year 2025 adjusted diluted earnings per share guidance has been updated to a range of $11.67 - $11.87 to incorporate this expense, investors should note that this IPR&D and milestones expense is inherently unpredictable and was not included in prior guidance beyond the first quarter of 2025.
The company is reiterating its second quarter 2025 adjusted diluted earnings per share guidance range as $2.84b - $2.88, inclusive of this newly disclosed expense. Investors are reminded that these are preliminary estimates and final results may differ.
02—Key points
Key Highlights
- AbbVie disclosed $823 million in pre-tax acquired IPR&D and milestones expense for Q2 2025.
- This expense is projected to reduce Q2 2025 GAAP and adjusted EPS by $0.42 per share.
- Full-year 2025 adjusted diluted EPS guidance is now projected between $11.67 and $11.87.
- Q2 2025 adjusted diluted EPS guidance is set at $2.84 - $2.88, incorporating the IPR&D and milestones impact.
- The company cautions that Q2 results are preliminary and subject to closing procedures.
- Acquired IPR&D and milestones expenses are not typically forecasted due to their uncertain nature.
- Exhibit 99.1 contains detailed guidance including the impact of acquired IPR&D and milestones expense.
03—Questions
Frequently Asked Questions
What is the primary reason for the adjustment to AbbVie's Q2 2025 earnings outlook?
The primary reason for the adjustment is a significant pre-tax expense of $823 million related to acquired in-process research and development (IPR&D) and milestones incurred in the second quarter of 2025. This expense is expected to negatively impact both GAAP and adjusted earnings per share by $0.42.
How does this acquired IPR&D and milestones expense affect AbbVie's full-year 2025 earnings guidance?
AbbVie has updated its full-year 2025 adjusted diluted earnings per share guidance range to $11.67 - $11.87 to reflect the impact of this expense. Previously, guidance beyond Q1 2025 did not include such costs due to their unpredictable nature.
Are the reported Q2 2025 earnings final?
No, the results for the second quarter ended June 30, 2025, are preliminary and have not been finalized. They are subject to the company's financial statement closing procedures, and there is no assurance that the final results will not differ from these initial estimates.
What is 'acquired IPR&D and milestones expense' and why is it not usually forecasted?
Acquired IPR&D and milestones expense relates to costs incurred upon entering into collaborations, licensing agreements, or acquiring other assets. AbbVie does not typically forecast these expenses because their future occurrence and timing are uncertain and depend on the successful execution of various business development activities.
04—Continue